ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,166.40
0.51%
다우존스 지수
38,589.16
-0.15%
Bitcoin
66,085.89
0.12%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 유럽
  5. EU
  6. Crossject (ALCJ)

  7. Crossject (ALCJ) 뉴스

ALCJ

Crossject (ALCJ)

Crossject
일자:
정렬 기준:
 검색 관련기사 보기:EU:ALCJ
일자시간출처헤드라인심볼기업
2024/06/1316:36GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
2024/06/1214:30GlobeNewswire Inc.Crossject appoints Dan Chiche, MD as Chief Medical Officer North AmericaEU:ALCJCrossject
2024/06/1214:30GlobeNewswire Inc.Crossject appoints Dan Chiche, MD as Chief Medical Officer North AmericaEU:ALCJCrossject
2024/06/1214:30GlobeNewswire Inc.Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du NordEU:ALCJCrossject
2024/06/0502:30GlobeNewswire Inc.Crossject announces highly successful closing of its €8 million rights offeringEU:ALCJCrossject
2024/06/0502:30GlobeNewswire Inc.Crossject announces highly successful closing of its €8 million rights offeringEU:ALCJCrossject
2024/06/0502:30GlobeNewswire Inc.Crossject annonce le vif succès de son augmentation de capital de 8 millions d’eurosEU:ALCJCrossject
2024/05/3017:30GlobeNewswire Inc.Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and TherapyEU:ALCJCrossject
2024/05/3017:30GlobeNewswire Inc.Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and TherapyEU:ALCJCrossject
2024/05/3017:30GlobeNewswire Inc.Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and TherapyEU:ALCJCrossject
2024/05/0300:30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
2024/05/0300:30GlobeNewswire Inc.Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in EuropeEU:ALCJCrossject
2024/05/0300:30GlobeNewswire Inc.Crossject signe une extension géographique de l'accord de commercialisation de ZEPIZURE® en EuropeEU:ALCJCrossject
2024/05/0102:05GlobeNewswire Inc.Crossject annonce le lancement d’une augmentation de capitalEU:ALCJCrossject
2024/04/2514:32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
2024/04/2514:32GlobeNewswire Inc.Crossject reports audited financial results for 2023EU:ALCJCrossject
2024/04/2514:32GlobeNewswire Inc.Crossject communique ses résultats financiers audités pour 2023EU:ALCJCrossject
2024/04/1023:30GlobeNewswire Inc.Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital socialEU:ALCJCrossject
2024/04/0301:35GlobeNewswire Inc.Crossject trading on Euronext to resume as usual on Wednesday April 3EU:ALCJCrossject
2024/04/0301:35GlobeNewswire Inc.La cotation sur l’action de Crossject à Euronext reprendra comme d’habitude le mercredi 3 avrilEU:ALCJCrossject
2024/04/0217:30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
2024/04/0217:30GlobeNewswire Inc.Crossject advances in its U.S. Strategy and reports Financial Results for 2023EU:ALCJCrossject
2024/04/0217:30GlobeNewswire Inc.Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023EU:ALCJCrossject
2024/03/0815:30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
2024/03/0815:30GlobeNewswire Inc.Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024EU:ALCJCrossject
2024/03/0815:30GlobeNewswire Inc.Crossject gender equality score reaches 96/100 in 2024EU:ALCJCrossject
2024/02/2716:30GlobeNewswire Inc.Crossject obtains a financing up to €12 million, in two tranchesEU:ALCJCrossject
2024/02/2716:30GlobeNewswire Inc.Crossject obtains a financing up to €12 million, in two tranchesEU:ALCJCrossject
2024/02/2716:30GlobeNewswire Inc.Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranchesEU:ALCJCrossject
2024/02/0701:30GlobeNewswire Inc.Crossject publie une mise à jour stratégique de ses priorités pour 2024EU:ALCJCrossject
 검색 관련기사 보기:EU:ALCJ

최근 히스토리

FX
USDEUR
US Dollar vs Euro
FX
USDJPY
US Dollar vs Yen
CCOM
US500
US 500
FX
USDGBP
US Dollar vs Sterling
USI
USTECH100
US Tech 100
NASDAQ
AAPL
Apple
PM
XAUUSD
Gold vs US Dollar
COIN
BTCUSD
Bitcoin
NYSE
MRK
Merck
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
CVX
Chevron
NASDAQ
AMZN
Amazon.com
COIN
SOLUSD
Solana
NYSE
BAC
Bank of America
AMEX
SPY
SPDR S&P 500
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유